Improving Access and Equity in VMS Treatment

November 5, 2024

Ryan Haumschild, PharmD, MS, MBA, CPEL
JoAnn V. Pinkerton, MD, FACOG, MSCP

Opinion

Video

Panelists discuss how to improve treatment rates for vasomotor symptoms (VMS) by identifying actionable steps, examining the influence of socioeconomic status on health care access, and proposing initiatives to ensure equitable care for all women experiencing menopause.

EP: 1.Understanding the Burden of Menopausal Vasomotor Symptoms

EP: 2.Barriers to VMS Treatment and Impact on Long-Term Health

Now Viewing

EP: 3.Improving Access and Equity in VMS Treatment

EP: 4.Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP: 5.Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP: 6.Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP: 7.Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP: 8.Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP: 9.Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP: 10.Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

Video content above is prompted by the following:

(FIFFICK) What steps can be taken to improve treatment rates of VMS associated with menopause?
(SMITH) How does the intersection of socioeconomic status and access to health care resources influence the management of VMS?
(PINKERTON) What initiatives could help bridge these gaps and ensure more equitable care for all women experiencing menopause?